OBJECTIVE: To assess the adequacy of reporting of non-inferiority trials alongside the consistency and utility of current recommended analyses and guidelines. DESIGN: Review of randomised clinical trials that used a non-inferiority design published between January 2010 and May 2015 in medical journals that had an impact factor >10 (JAMA Internal Medicine, Archives Internal Medicine, PLOS Medicine, Annals of Internal Medicine, BMJ, JAMA, Lancet and New England Journal of Medicine). DATA SOURCES: Ovid (MEDLINE). METHODS: We searched for non-inferiority trials and assessed the following: choice of non-inferiority margin and justification of margin; power and significance level for sample size; patient population used and how this was defined; ...
In drug, device and behavioral clinical trials, patient withdrawal, loss-to-follow-up, and non-compl...
Background Non-inferiority and equivalence trials aim to determine whether a new treatment is goo...
Non-inferiority trials are used to assess whether the effect of a new drug is not worse than an acti...
ObjectiveTo assess the adequacy of reporting of non-inferiority trials alongside the consistency and...
BACKGROUND: A non-inferiority (NI) trial is intended to show that the effect of a new treatment is n...
A non-inferiority (NI) trial is intended to show that the effect of a new treatment is not worse tha...
The non-inferiority trial design has gained popularity within the last decades to compare a new trea...
Clinical trials are an essential part of the drug development life cycle. There are different types ...
There is a knowledge gap in designing so-called “non-inferiority trials”, which aim to show whether ...
BACKGROUND: There is no consensus on the preferred method for defining the non-inferiority margin in...
Background There is concern that non-inferiority trials might be deliberately designed to conceal th...
Objectives: Non-inferiority (NI) randomized clinical trials (RCTs) commonly evaluate efficacy of new...
Abstract Background Non-inferiority and equivalence trials require tailored methodology and therefor...
Background There is no consensus on the preferred method for defining the non-inferiority margin in ...
BACKGROUND: The classification of phase 3 trials as superiority or non-inferiority has become routin...
In drug, device and behavioral clinical trials, patient withdrawal, loss-to-follow-up, and non-compl...
Background Non-inferiority and equivalence trials aim to determine whether a new treatment is goo...
Non-inferiority trials are used to assess whether the effect of a new drug is not worse than an acti...
ObjectiveTo assess the adequacy of reporting of non-inferiority trials alongside the consistency and...
BACKGROUND: A non-inferiority (NI) trial is intended to show that the effect of a new treatment is n...
A non-inferiority (NI) trial is intended to show that the effect of a new treatment is not worse tha...
The non-inferiority trial design has gained popularity within the last decades to compare a new trea...
Clinical trials are an essential part of the drug development life cycle. There are different types ...
There is a knowledge gap in designing so-called “non-inferiority trials”, which aim to show whether ...
BACKGROUND: There is no consensus on the preferred method for defining the non-inferiority margin in...
Background There is concern that non-inferiority trials might be deliberately designed to conceal th...
Objectives: Non-inferiority (NI) randomized clinical trials (RCTs) commonly evaluate efficacy of new...
Abstract Background Non-inferiority and equivalence trials require tailored methodology and therefor...
Background There is no consensus on the preferred method for defining the non-inferiority margin in ...
BACKGROUND: The classification of phase 3 trials as superiority or non-inferiority has become routin...
In drug, device and behavioral clinical trials, patient withdrawal, loss-to-follow-up, and non-compl...
Background Non-inferiority and equivalence trials aim to determine whether a new treatment is goo...
Non-inferiority trials are used to assess whether the effect of a new drug is not worse than an acti...